Ibrutinib and rituximab trigger 95 percent response rate among CLL patients HealthCanal.com Nearly all of the high-risk chronic lymphocytic leukemia patients in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib and the antibody rituximab, researchers reported today, at the 55th Annual Meeting of the American ... |
